AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06019442 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief alcohol intervention (Health4Her-Automated)
Description: Embedded within the lifestyle health promotion provided in both conditions, participants randomised to the experimental condition will receive a brief alcohol intervention. The brief alcohol intervention will comprise information and behaviour-change content regarding alcohol consumption, including: messaging around alcohol risks/harms (with a focus on alcohol use and breast cancer risk), positive-framed messaging on the health benefits of reducing alcohol intake, and alcohol harm-reduction / behaviour change strategies (e.g. drink counting, goal setting, behaviour substitution, problem solving).~Post-session information will be provided via email (i.e. electronic brochure summarising brief alcohol intervention content).
Study NCT06019442 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle health promotion
Description: Lifestyle health promotion, focused on physical activity and maintaining a healthy weight for reducing breast cancer risk, will be provided.~Post-session information will be provided via email (i.e. electronic brochure summarising nutrition for maintaining a healthy weight).
Study NCT06019442 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle health promotion
Description: Lifestyle health promotion, focused on physical activity and maintaining a healthy weight for reducing breast cancer risk, will be provided.~Post-session information will be provided via email (i.e. electronic brochure summarising nutrition for maintaining a healthy weight).
Study NCT05083637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L- carnitine oral solution
Description: The L-carnitine syrup formulation will be provided to study participant at nutritional rehabilitation unit (NRU) under controlled set-up
Study NCT05083637 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo formulation will be provided to study participant at nutritional rehabilitation unit (NRU) under controlled set-up
Study NCT04800731 — intervention group
Intervention type: OTHER
Intervention: observation no intervention
Description: no intervention
Study NCT04864548 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 virus
Description: The SARS-COV-2 challenge virus strain was originally obtained from a nose/throat swab taken from a patient who developed respiratory symptoms consistent with COVID-19. The isolate was plaque purified to obtain a 'single' virus entity. The selected plaque, B1, was subsequently manufactured in accordance with GMP at the Great Ormond Street manufacturing suite.
Study NCT06318702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: is an education program implemented to raise women's awareness about reproductive health and to help them adopt healthy habits.
Study NCT04810377 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-guided gastroenterostomy
Description: First after an upper endoscopy is performed, a catheters passed throughout the endoscope channel and with x-ray verification, a guide wire is passed up to the third portion of duodenal loop. then small intestinal is filled with saline solution up to 1500cc and contrast solution. Then an endoscopic ultrasound examination will be carried out where a loop of the small intestine that is located less than 2 cm apart from the gastric wall will be looked for. Once the intestinal loop is identified a direct antegrade puncture will be performed with a luminal apposition prosthesis release system . Finally, correct position is verified with x-ray and we will look for any misplacement or leakage during this process or the presence of bleeding. Endoscopic treatment will be performed if necessary. Subsequently, the participants will go to monthly follow-up with clinical evaluation, laboratory and radiological test will be carried out until the participants dies.
Study NCT05180097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000mg/m2 IV, 30 mins D1, D8
Study NCT05180097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 40mg daily PO, D1-D4
Study NCT05180097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 75mg/m2 IV, 1 hour, D1
Study NCT05180097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brentuximab vedotin
Description: 1.8 mg/kg IV, 30 mins, Q21 days
Study NCT05180097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: 200mg IV, 30 mins, Q 21 days
Study NCT06459180 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sacituzumab Tirumotecan
Description: IV infusion
Study NCT05617287 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Semaine Menopause Supplement
Description: Synergistic Dietary Supplement
Study NCT06460740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4-7-8 breathing technique
Description: Treatment will be given 18 exercise sessions per month (four to five times per week). The patient at first will be directed to sit or lie down, in which manner they feel sense of comfort. Then they are asked to exhale completely through mouth emptying their lungs. Then closing their lips and inhaling silently through nose while counting on the count of 4 seconds, holding their breath for a count of 7 seconds and exhale slowly through semi-closed lips making a Whoosh sound for a count of 8 seconds. Inhale, hold breath, and exhale ratio of 4:7:8. In aerobic protocol, F (frequency) subjects will receive training up to 18 exercise sessions per month (four to five times per week). I (intensity) subjects will receive training up to intensity of 70 to 75 %, T \& T (Time and Type) subjects will receive training up to 20 minutes of bicycling.
Study NCT06460740 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stationary Cycling
Description: In aerobic protocol, F (frequency) subjects will receive training up to 18 exercise sessions per month (four to five times per week). I (intensity) subjects will receive training up to intensity of 70 to 75 %, T \& T (Time and Type) subjects will receive training up to 20 minutes of bicycling
Study NCT06523829 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GROUP GIVEN VIDEO TRAINING
Description: Video-based training was given to this group.
Study NCT06459180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: IV infusion
Study NCT06459180 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tisotumab Vedotin
Description: IV infusion
Study NCT06459180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: IV infusion
Study NCT06459180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: IV infusion
Study NCT06459180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: IV infusion
Study NCT06459180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: IV infusion
Study NCT06639503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain
Description: 5mL 0.25% bupivacain
Study NCT03909594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine
Study NCT03909594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Bupivacaine
Study NCT03909594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine
Study NCT00012597 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Web-based telemedicine system for assessment of status of pressure ulcers
Study NCT04862221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose methylprednisolone
Description: Subjects in the high-dose methylprednisolone arm will receive an initial dose of methylprednisolone IV 10 mg/kg/day for 3 days and 5 mg/kg/day on Day 4. Normal saline will be used as placebo pre-medications and infusions given at the same volume and duration as the eATG infusions.
Study NCT04862221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Equine anti-thymocyte globulin
Description: Subjects will receive eATG IV 40 mg/kg/day on Days 1- 4. Day 1 eATG infusion is run over 8 hours and Day 2-4 infusions are run over 4 hours.
Study NCT04862221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Subjects will receive prednisolone 1 mg/kg on Days 5-13 followed by a gradual taper with discontinuation at 42 Days as indicated below.~Days 5 - 13 Prednisolone PO 1 mg/kg/day (max 50 mg/day)~Days 14- 20 Prednisolone PO 0.5 mg/kg/day (max 25 mg/day)~Days 21 - 27 Prednisolone PO 0.3 mg/kg/day (max 15 mg/day)~Days 28 - 34 Prednisolone PO 0.1 mg/kg/day (max 5 mg/day)~Days 35 - 41 Prednisolone PO 0.1 mg/kg every OTHER day (max 5 mg every other day)~Day 42 Discontinue
Study NCT04862221 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for prednisolone
Description: Subjects will receive 1 mg/kg/day of oral placebo for prednisolone on days 5-13 followed by a gradual taper to discontinuation at 42 days as indicated below. Subjects receiving oral placebo will be given a solution that closely resembles the treatment drug.~Days 5 - 13 Placebo for Prednisolone PO 1 mg/kg/day (max 50 mg/day)~Days 14- 20 Placebo for Prednisolone PO 0.5 mg/kg/day (max 25 mg/day)~Days 21 - 27 Placebo for Prednisolone PO 0.3 mg/kg/day (max 15 mg/day)~Days 28 - 34 Placebo for Prednisolone PO 0.1 mg/kg/day (max 5 mg/day)~Days 35 - 41 Placebo for Prednisolone PO 0.1 mg/kg every OTHER day (max 5 mg every other day)~Day 42 Discontinue
Study NCT04862221 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for infusions
Description: Subjects randomized to the supportive care alone arm will receive normal saline in place of all study treatments (skin test, premedication and IV infusions) on Days 1-4 given at the same volume and duration as the eATG infusions.
Study NCT04862221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Subjects in the eATG arm will receive pre-treatment medication diphenhydramine IV 1 mg/kg prior to start of eATG infusion.
Study NCT04862221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Subjects in the eATG arm will receive pre-treatment medication methylprednisolone IV 1 mg/kg prior to start of eATG infusion.
Study NCT06365970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: An anti-cancer medication that helps to repair DNA when it becomes damaged, known as a PARP inhibitor.
Study NCT06365970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: An anti-cancer medication that is a programmed death receptor-1 -blocking monoclonal antibody.
Study NCT05090332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial Gun
Description: Vibration massage applied for five Minutes directly on the trigger point
Study NCT05090332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: For dry needling the outer skin should be clean with alcohol and the taut band should be placed between thumb and index finger. Without damaging any nerve or artery the needle is passed though the muscle into the trigger point and breaking it to relief pain
Study NCT04978766 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Book Reading
Description: The intervention is a package including five children's books and information on how to practice interactive book reading. Information includes 36 audiovisual products delivered via text messaging over a 12-week period. Products include:~1. An introductory video about interactive book reading, along with a written list of recommendations on how to practice interactive book reading.~2. Two videos of child development experts explaining the benefits of interactive reading.~3. Thirty written text messages strengthening content provided in the videos.~4. Three audio messages guiding the progress of the intervention.~Based on Abraham and Michie's (2008) taxonomy of behavior change techniques, one audiovisual product prompts specific goal settings, 13 provide instruction, one provides information on consequences, 10 prompt practice, three use follow-up prompts, one prompts self-monitoring of behavior, one models or demonstrates the behavior and six prompt barrier identification.
Study NCT05687630 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: elastic band resisted exercise
Description: muscle strengthening exercise, 10-15 times of each set, for 3 sets
Study NCT05687630 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: elastic band resisted exercise
Description: muscle strengthening exercise, 10-15 times of each set, for 3 sets
Study NCT04926818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fingolimod
Description: Fingolimod capsule administered orally once daily at a dose of either 0.5 mg or 0.25 mg (depending on patient's body weight).
Study NCT04926818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Ofatumumab as a solution for injection in an autoinjector containing 20 mg ofatumumab (50 mg/mL, 0.4 mL content) for subcutaneous administration. A loading dose at Day1, Day 7 and Day 14 and then injections every 4 weeks/ 6 weeks (depending on patient's body weight).
Study NCT04926818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siponimod
Description: Siponimod tablet administered orally once daily. Titration period, Day 1 to Day 6, first dose is either 0.1 mg or 0.25 mg up to daily dose of either 0.5 mg, 1 mg or 2 mg (depending on CYP2C9 genotype and body weight).
Study NCT04926818 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fingolimod placebo
Description: Fingolimod matching placebo capsule
Study NCT04926818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Siponimod placebo
Description: Siponimod matching placebo tablet
Study NCT04926818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ofatumumab placebo
Description: Ofatumumab matching placebo autoinjector
Study NCT06237231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DIT112
Description: DIT112 tablet
Study NCT06237231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DIPYRONE
Description: Dipyrone tablet 1.000mg
Study NCT06237231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TRAMADOL
Description: Tramadol tablet 50mg
Study NCT06237231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DIT112 Placebo
Description: DIT112 placebo tablet
Study NCT06237231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipyrone Placebo
Description: Dipyrone placebo tablet
Study NCT06237231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dipyrone Placebo
Description: Dipyrone placebo tablet
Study NCT06237231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol Placebo
Description: Tramadol placebo capsule
Study NCT06237231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol Placebo
Description: Tramadol placebo capsule
Study NCT06158165 — intervention group
Intervention type: DEVICE
Intervention: Mostcare (Vytech, Vygon, Padua, Italy)
Description: Parameters were observed through the utilization of the MostCare (Vytech, Vygon, Padua, Italy) device employing the Pressure Recording Analytic Method (PRAM).
Study NCT04780269 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Induction of labor with Foley catheter
Description: A Foley catheter will be introduced transcervically in women allocated in this group, with the aid of a vaginal speculum after cervical cleaning with an aseptic solution. The balloon will be inflated with 60 mL of sterile 0.9%% sodium chloride (NaCl) after insertion past the internal os. The external end of the catheter is taped to the inner thigh without applying any traction or tension.
Study NCT04780269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction of labor with PGE2
Description: PGE2 (1mg) will be inserted into the posterior vaginal fornix. Women will be assigned one hour of bed rest while continuously monitored by cardiotocography.
Study NCT05689931 — intervention group
Intervention type: BIOLOGICAL
Intervention: Mepolizumab
Description: Mepolizumab is administered by subcutaneous injection with guideline recommended patient selection and dosing for treatment of eosinophilic asthma.~Accordingly, the Mepolizumab treatment is given as add-on therapy to standard inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)
Study NCT05689931 — intervention group
Intervention type: DRUG
Intervention: Standard inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)
Description: Routine asthma treatment with inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)
Study NCT06277752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dose-5 group
Description: IBI128 300mg po. QD(Quaque Die)
Study NCT06277752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dose-1 group
Description: IBI128 25mg po. QD(Quaque Die)
Study NCT06277752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dose-2 group
Description: IBI128 50mg po. QD(Quaque Die)
Study NCT06277752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dose-4 group
Description: IBI128 200mg po. QD(Quaque Die)
Study NCT06277752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dose-3 group
Description: IBI128 100mg po. QD(Quaque Die)
Study NCT04987138 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Zenflow Spring System
Description: The Zenflow Spring Implant is an electropolished and passivated nickel titanium alloy (nitinol) implant. The implant is constructed from a single wire strand formed into ring elements connected by spine sections. There are four sizes of implants ranging from 16 mm to 24 mm in length and 14 mm to 16 mm in diameter to implant in the subject's prostatic urethra. The implant is placed in the urethra using a custom delivery catheter and cystoscope (Spring Scope). The implant is intended to be permanent but can be removed if necessary.
Study NCT04987138 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zenflow Spring System
Description: The Zenflow Spring Implant is an electropolished and passivated nickel titanium alloy (nitinol) implant. The implant is constructed from a single wire strand formed into ring elements connected by spine sections. There are four sizes of implants ranging from 16 mm to 24 mm in length and 14 mm to 16 mm in diameter to implant in the subject's prostatic urethra. The implant is placed in the urethra using a custom delivery catheter and cystoscope (Spring Scope). The implant is intended to be permanent but can be removed if necessary.
Study NCT04987138 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: A18 Fr Foley Catheter is placed into the patient's bladder. To mimic the Treatment Arm procedure, the Foley Catheter balloon will be inflated in the bladder. Once inflated, slight tension will be applied against the subject's bladder neck. While tension is being applied the site staff will follow a script to simulate the Zenflow procedural steps. Additionally, devices will be used to produce mock deployment sounds of the Zenflow procedure. Once complete, the balloon will be deflated and the catheter will be removed, completing the procedure.
Study NCT05364411 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HYpofractionated, Dose-redistributed RAdiotherapy (HYDRA)
Description: 20 daily fractions, 5 times per week
Study NCT05364411 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: conventional fractionated radiotherapy
Description: 35 daily fractions, 5 times per week
Study NCT04857099 — intervention group
Intervention type: OTHER
Intervention: Data extraction from medical files
Description: Data extraction from medical files
Study NCT06538506 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RehUp BCI Intervention
Description: Participants will be seated wearing a cap on their head containing surface electrodes connected to a computer/laptop. The laptop employs machine learning algorithms and uses the scalp electroencephalogram (EEG) signals from the scalp's surface to control a robotic arm which supports the patient's stroke-affected arm. The machine learning algorithms rapidly interpret EEG signals and adjust the outgoing movement commands to the robot based on an individual's responses to stimuli. The participant will be wearing a VR headset. The VR displays visual stimulus in time with the robotic arm. Based on information from the EEG, the participant is able to animate their robotic arm and receive visual task-based feedback in the VR.
Study NCT06538506 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Therapy
Description: The study therapist will focus on 3 activities (\~15 minutes each/session): passive range of motion exercises, motor imagery, and mirror therapy. These activities were chosen as they are all passive activities that are commonly used in a patient with severe impairment of the post-stroke arm and hand. Each session will last \~1hour including set up and switching between activities.
Study NCT06509191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention 1
Description: Melatonin 5mg/day
Study NCT06509191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention 2
Description: Melatonin 8 mg/day
Study NCT06129617 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hemodialysis
Description: 5 treatments with hemodialysis on day 1, 2, 3, 5 and 7
Study NCT06129617 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADVOS
Description: 5 treatments with ADVOS on day 1, 2, 3, 5 and 7